Target intelligence / Profile preview

Acyl carrier protein–β-ketoacyl-ACP synthase complex (ACP-KAS complex)

Target
ACP-KAS complex
Molecular classification
Enzyme complex, Transferase, Condensing enzyme
01

Overview

The Acyl carrier protein–β-ketoacyl-ACP synthase (ACP-KAS) complex is a fundamental component of the Type II fatty acid synthesis (FAS II) pathway in bacteria (White et al., 2005, Annu Rev Biochem). This complex involves the interaction between the acyl carrier protein (ACP), which carries the growing acyl chain, and various β-ketoacyl-ACP synthases (FabH, FabB, and FabF) that catalyze the condensation of malonyl-ACP with an acyl group (Zhang et al., 2001, J Biol Chem). This step is the primary driver of fatty acid chain elongation, which is essential for the formation of the bacterial cell membrane and other lipid-derived structures. Because the bacterial FAS II system is structurally distinct from the human Type I fatty acid synthase (FAS I), it is a highly selective target for antibiotic development (Wright & Reynolds, 2007, Curr Opin Microbiol). Natural products such as platensimycin and platencin have been identified as potent inhibitors of the KAS enzymes within this complex, showing significant efficacy against multi-drug resistant pathogens like MRSA (Wang et al., 2006, Nature). Despite their potency, challenges remain in optimizing these inhibitors for clinical use due to poor pharmacokinetic properties and the potential for rapid resistance development (Parsons & Rock, 2011, Prog Lipid Res).

Other names
ACP-FabH complexACP-FabB complexACP-FabF complex3-oxoacyl-[acyl-carrier-protein] synthase complexBacterial fatty acid synthase II condensing complex
02

Mechanism of action

Inhibition of the condensation reaction between malonyl-ACP and an acyl group, preventing fatty acid chain elongation.

03

Biological functions

Fatty acid biosynthesisLipid metabolismCell wall synthesisMembrane biogenesis
04

Disease associations

Bacterial infection
05

Safety considerations

Development of bacterial resistancePoor pharmacokinetic properties of current lead compoundsPotential cross-reactivity with human mitochondrial fatty acid synthesis
06

Interacting drugs

Platensimycin

3 more in the full profile.

07

Biomarkers

Bacterial growth inhibitionMalonyl-CoA accumulationReduction in long-chain fatty acid production

Beyond the preview

Go deeper on Acyl carrier protein–β-ketoacyl-ACP synthase complex (ACP-KAS complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acyl carrier protein–β-ketoacyl-ACP synthase complex (ACP-KAS complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call